525 related articles for article (PubMed ID: 18249172)
21. The androgen receptor confers protection against diet-induced atherosclerosis, obesity, and dyslipidemia in female mice.
Fagman JB; Wilhelmson AS; Motta BM; Pirazzi C; Alexanderson C; De Gendt K; Verhoeven G; Holmäng A; Anesten F; Jansson JO; Levin M; Borén J; Ohlsson C; Krettek A; Romeo S; Tivesten Å
FASEB J; 2015 Apr; 29(4):1540-50. PubMed ID: 25550469
[TBL] [Abstract][Full Text] [Related]
22. The influence of repeated administration of poloxamer 407 on serum lipoproteins and protease activity in mouse liver and heart.
Korolenko TA; Tuzikov FV; Johnston TP; Tuzikova NA; Kisarova YA; Zhanaeva SY; Alexeenko TV; Zhukova NA; Brak IV; Spiridonov VK; Filjushina EE; Cherkanova MS; Monoszon AA
Can J Physiol Pharmacol; 2012 Nov; 90(11):1456-68. PubMed ID: 23181274
[TBL] [Abstract][Full Text] [Related]
23. Apolipoprotein A-IV expression in mouse liver enhances triglyceride secretion and reduces hepatic lipid content by promoting very low density lipoprotein particle expansion.
VerHague MA; Cheng D; Weinberg RB; Shelness GS
Arterioscler Thromb Vasc Biol; 2013 Nov; 33(11):2501-8. PubMed ID: 24030551
[TBL] [Abstract][Full Text] [Related]
24. Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia.
Chong T; Naples M; Federico L; Taylor D; Smith GJ; Cheung RC; Adeli K
Atherosclerosis; 2006 Mar; 185(1):21-31. PubMed ID: 16002078
[TBL] [Abstract][Full Text] [Related]
25. Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes.
Vergès B
Atherosclerosis; 2010 Aug; 211(2):353-60. PubMed ID: 20189175
[TBL] [Abstract][Full Text] [Related]
26. Catabolism of lipoproteins and metabolic syndrome.
Therond P
Curr Opin Clin Nutr Metab Care; 2009 Jul; 12(4):366-71. PubMed ID: 19474714
[TBL] [Abstract][Full Text] [Related]
27. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis.
Semple RK; Sleigh A; Murgatroyd PR; Adams CA; Bluck L; Jackson S; Vottero A; Kanabar D; Charlton-Menys V; Durrington P; Soos MA; Carpenter TA; Lomas DJ; Cochran EK; Gorden P; O'Rahilly S; Savage DB
J Clin Invest; 2009 Feb; 119(2):315-22. PubMed ID: 19164855
[TBL] [Abstract][Full Text] [Related]
28. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
29. Ces3/TGH deficiency improves dyslipidemia and reduces atherosclerosis in Ldlr(-/-) mice.
Lian J; Quiroga AD; Li L; Lehner R
Circ Res; 2012 Sep; 111(8):982-90. PubMed ID: 22872154
[TBL] [Abstract][Full Text] [Related]
30. Obesity potentiates development of fatty liver and insulin resistance, but not atherosclerosis, in high-fat diet-fed agouti LDLR-deficient mice.
Coenen KR; Hasty AH
Am J Physiol Endocrinol Metab; 2007 Aug; 293(2):E492-9. PubMed ID: 17566116
[TBL] [Abstract][Full Text] [Related]
31. Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice.
Zhou E; Li Z; Nakashima H; Choukoud A; Kooijman S; Berbée JFP; Rensen PCN; Wang Y
Pharmacol Res; 2021 May; 167():105524. PubMed ID: 33667684
[TBL] [Abstract][Full Text] [Related]
32. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity.
Kwiterovich PO
Am J Cardiol; 2002 Oct; 90(8A):30i-47i. PubMed ID: 12419479
[TBL] [Abstract][Full Text] [Related]
33. Constitutive androstane receptor activation decreases plasma apolipoprotein B-containing lipoproteins and atherosclerosis in low-density lipoprotein receptor-deficient mice.
Sberna AL; Assem M; Xiao R; Ayers S; Gautier T; Guiu B; Deckert V; Chevriaux A; Grober J; Le Guern N; Pais de Barros JP; Moore DD; Lagrost L; Masson D
Arterioscler Thromb Vasc Biol; 2011 Oct; 31(10):2232-9. PubMed ID: 21778422
[TBL] [Abstract][Full Text] [Related]
34. Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression.
Haas JT; Miao J; Chanda D; Wang Y; Zhao E; Haas ME; Hirschey M; Vaitheesvaran B; Farese RV; Kurland IJ; Graham M; Crooke R; Foufelle F; Biddinger SB
Cell Metab; 2012 Jun; 15(6):873-84. PubMed ID: 22682225
[TBL] [Abstract][Full Text] [Related]
35. Relationship between noninvasive scores of nonalcoholic fatty liver disease and nuclear magnetic resonance lipoprotein abnormalities: A focus on atherogenic dyslipidemia.
Amor AJ; Pinyol M; Solà E; Catalan M; Cofán M; Herreras Z; Amigó N; Gilabert R; Sala-Vila A; Ros E; Ortega E
J Clin Lipidol; 2017; 11(2):551-561.e7. PubMed ID: 28502513
[TBL] [Abstract][Full Text] [Related]
36. Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase.
Shimada M; Ishibashi S; Inaba T; Yagyu H; Harada K; Osuga JI; Ohashi K; Yazaki Y; Yamada N
Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7242-6. PubMed ID: 8692976
[TBL] [Abstract][Full Text] [Related]
37. The role of hepatic Surf4 in lipoprotein metabolism and the development of atherosclerosis in apoE
Shen Y; Gu HM; Zhai L; Wang B; Qin S; Zhang DW
Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Oct; 1867(10):159196. PubMed ID: 35803528
[TBL] [Abstract][Full Text] [Related]
38. Genetic disruption of myostatin reduces the development of proatherogenic dyslipidemia and atherogenic lesions in Ldlr null mice.
Tu P; Bhasin S; Hruz PW; Herbst KL; Castellani LW; Hua N; Hamilton JA; Guo W
Diabetes; 2009 Aug; 58(8):1739-48. PubMed ID: 19509018
[TBL] [Abstract][Full Text] [Related]
39. Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance.
Grundy SM
Clin Cornerstone; 2006; 8 Suppl 1():S21-7. PubMed ID: 16903166
[TBL] [Abstract][Full Text] [Related]
40. Lipolytic enzymes, metablic syndrome and atherosclerosis (revisiting and revising a 40 years old study).
Cucuianu M; Brudaşca I
Rom J Intern Med; 2008; 46(2):99-104. PubMed ID: 19284080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
